Showing 5121-5130 of 9749 results for "".
- Study: Head and Neck Melanomas Show Unique Patternshttps://practicaldermatology.com/news/study-head-and-neck-melanomas-show-unique-patterns/2470807/A recent study published in the Journal of the American Academy of Dermatology reports that cutaneous melanomas located on the head and neck (CHNM) exhibit distinct clinicopathological features and treatment outcomes compared to melanomas at other anatomical sites (CMOS). Researc
- Allergy-Friendly Detergents Safe for Atopic Dermatitis Patientshttps://practicaldermatology.com/news/allergy-friendly-detergents-safe-atopic-dermatitis-patients/2470779/A recent clinical study found that two laundry detergents marketed for sensitive skin do not negatively impact the skin microbiome or worsen symptoms of atopic dermatitis (AD). The study was conducted in 41 participants diagnosed with AD. For the present study, the researchers evaluated th
- Study: Ongoing Inequities in Dermatology Productivity Metricshttps://practicaldermatology.com/news/study-ongoing-inequities-dermatology-productivity-metrics/2470777/A new study in JAMA Dermatology revealed that while the 2021 Medicare physician fee schedule updates reduced inequities in work relative value units (wRVUs) for outpatient dermatology visits, significant disparities based on patient demographics persist. Analyzing data from 89,656
- New Computational System Evaluates Vitiligo Repigmentation Rateshttps://practicaldermatology.com/news/new-computational-system-evaluates-vitiligo-repigmentation-rates/2470766/A research team from Shenzhen People’s Hospital have developed a computational system for evaluating repigmentation rates in vitiligo patients, according to a new paper in the Journal of Investigative Dermatology. The retrospective study, conducted from June 2019 to November 2022
- National Rosacea Society Introduces Informational Postcardhttps://practicaldermatology.com/news/national-rosacea-society-introduces-informational-postcard/2470763/The National Rosacea Society (NRS) announced today that it has released a new educational postcard to raise awareness about rosacea, a chronic skin condition affecting over 16 million Americans. Titled “Rosacea: A Common Disease, Uncommonly Treated,” the resource is designed for d
- Study Explores How Moderate to Severe Hand Eczema Affects Quality of Lifehttps://practicaldermatology.com/news/moderate-severe-hand-eczema-quality-life-challenges-explored/2470762/Even mild hand eczema can significantly impair one's quality of life and mental health, according to a new study. The findings, presented at the recent Revolutionizing Atopic Dermatitis (RAD) Conference, spanned data collected from 2013 to 2020, addressed the outsized impact of hand eczem
- Extended Analysis Confirms Favorable Safety for Upadacitinibhttps://practicaldermatology.com/news/extended-analysis-confirms-favorable-safety-upadacitinib/2470761/Results from a long-term integrated analysis support the favorable safety profile of upadacitinib for moderate-to-severe atopic dermatitis (AD) in adolescents and adults. The analysis, presented at the recent Revolutionizing Atopic Dermatitis (RAD) Conference, included over 9,000 patient-y
- ADapt Study: Lebrikizumab Improves Skin and Quality of Life in ADhttps://practicaldermatology.com/news/study-lebrikizumab-improves-skin-and-quality-life-ad/2470753/Results from the phase 3b ADapt study presented at the recent Revolutionizing Atopic Dermatitis (RAD) Conference indicated lebrikizumab (LEB) improved skin clearance, reduced itch, and enhanced quality of life in patients with moderate-to-severe atopic dermatitis (AD) in whom dupilumab (DUPI) was
- Arcutis Submits sNDA for Roflumilast for Children 2 to 5 With ADhttps://practicaldermatology.com/news/arcutis-submits-snda-roflumilast-children-2-5-ad/2470667/Arcutis Biotherapeutics, Inc. announced the submission of a supplemental New Drug Application (sNDA) to the US Food and Drug Administration (FDA) for roflumilast (ZORYVE) cream 0.05%, a once-daily, next-generation phosphodiesterase 4 (PDE4) inhibitor, for the topical treatment of mild-to-moderate
- AARS Scholar Grant to Be Used for Antibiotics Researchhttps://practicaldermatology.com/news/aars-scholar-grant-be-used-antibiotics-research/2470665/The American Acne and Rosacea Society (AARS) announced that the 2024 AARS Clinical Research Scholar Grant has been provided to Jean McGee, MD, PhD, of the Department of Dermatology at Brigham and Women’s Hospital in Boston. Additionally, AARS Clinical Research Grants are being provided to